These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 35165856)

  • 1. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
    Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
    Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
    Aslesh T; Erkut E; Yokota T
    Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
    [No Abstract]   [Full Text] [Related]  

  • 7. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
    Laurent M; Geoffroy M; Pavani G; Guiraud S
    Cells; 2024 May; 13(10):. PubMed ID: 38786024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
    Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
    Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR Correction of Duchenne Muscular Dystrophy.
    Min YL; Bassel-Duby R; Olson EN
    Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
    Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
    Chemello F; Olson EN; Bassel-Duby R
    Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
    Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
    Gene; 2023 May; 867():147358. PubMed ID: 36914142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.